Comment from National Leiomyosarcoma Foundation

Summary: The National Leiomyosarcoma Foundation (NLMSF) supports the FDA's initiative to explore drug repurposing for diseases with unmet medical needs, specifically requesting that sarcoma be prioritized. They argue that drug repurposing is a promising strategy for rare cancers due to limited commercial incentives for traditional development and the urgent need for new treatment options for patients.